BLRX
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- BioLineRx and Hemispherian reported preclinical data showing strong synergy between GLIX1 and a PARP inhibitor in ovarian cancerJul 8, 2026
- BioLineRx and Hemispherian present new GLIX1 data showing strong anti-tumor activity in glioblastoma modelsMay 19, 2026
- BioLineRx and Hemispherian dosed the first patient in the Phase 1/2a study of GLIX1 for glioblastoma treatmentApr 28, 2026
- BioLineRx initiated a Phase 1/2a study of GLIX1 for glioblastomaMar 26, 2026
- Hemispherian announced USPTO Notice of Allowance for key GLIX1 patent covering majority of solid tumorsNov 19, 2025